Probably been posted before, but the ODAC Briefing Document (https://www.fda.gov/media/140988/download) gave cause for caution on results to date. They clearly needed to be convinced of the technology, safety and consistency of product.
Trials continue, so I personally don't see the FDA advice as a setback, but rather an opportunity for Mesoblast to prove beyond doubt the efficacy of the Remestemcel-L treatment.
It took a while for people to get their heads around plugging a car in to a power outlet and running it on electricity. Such is life.
Ann: Update on BLA for Graft Versus Host Disease, page-236
-
- There are more pages in this discussion • 320 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.16 |
Change
0.005(0.43%) |
Mkt cap ! $1.318B | |||
| Open | High | Low | Value | Volume |
| $1.15 | $1.17 | $1.13 | $3.743M | 3.261M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 78561 | $1.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.16 | 114667 | 4 |
View Market Depth
| Last trade - 16.10pm 22/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |